Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 863.87B +45.7% |
| Revenue (ttm) | 69.73B +49.6% |
| Net Income | 23.38B +93.6% |
| EPS | 26.07 +94.8% |
| Shares Out | n/a |
| PE Ratio | 36.95 |
| Forward PE | 28.69 |
| Dividend | 5.52 (0.55%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 441 |
| Open | 976.20 |
| Previous Close | 966.00 |
| Day's Range | 975.10 - 1,036.20 |
| 52-Week Range | 537.40 - 1,085.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Wednesday's Final Takeaways: GOOGL AI Chief Leaves, GLP-1 Boosts LLY
Marley Kayden and Sam Vadas wrap up Wednesday's session with a few overlooked headlines to keep on the radar. Marley details a cautionary note from Bank of America (BAC) CEO Brian Moynihan before turn...
Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026
CNBC Business News Update with Peter Schacknow - Markets & Business News With Expert Analysis From Top Business Names. Visit CNBC.com For More.
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Inside Out: LLY and the Future of Weight Loss Drugs
Matt Tuttle can't quite pronounce the name of Eli Lilly's (LLY) oral weight-loss drug, but that doesn't stop him from understanding its significance to the healthcare company's future. He reacts to th...
Eli Lilly stock surges 6% after Q2 earnings beat driven by Mounjaro, Zepbound
Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit...
LLY Earnings: Eli Lilly’s Stock Jumps on Blowout Financial Results
The company continues to dominate the obesity drug market.
Eli Lilly and Company Earnings Call Transcript: Q2 2026
Q2 2026 saw 48% revenue growth year-over-year, driven by strong performance across all therapeutic areas and geographies, with key products like MOUNJARO and ZEPBOUND leading. Full-year guidance was raised, major regulatory and pipeline milestones were achieved, and access to obesity medicines expanded significantly.
Eli Lilly and Company Slides: Q2 2026
Eli Lilly and Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Eli Lilly and Company Earnings release: Q2 2026
Eli Lilly and Company released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Eli Lilly and Company Quarterly report: Q2 2026
Eli Lilly and Company has published its Q2 2026 quarterly earnings report on August 5, 2026.
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.
Eli Lilly narrows FY26 EPS view to $35.50-$36.50 from $35.50-$37.00
Consensus $34.54. Raises FY26 revenue view to $85B-$87B from $82B-$85B, consensus $85.15B. The company said, “The first half of 2026 also benefited from sales based milestones and adjustments for reba...
Lilly's revenue soars 48%, driven by demand of its GLP-1s
Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Eli Lilly reports Q2 EPS $8.38, consensus $6.58
Reports Q2 revenue $22.97B, consensus $20.69B. “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance,” said David A. Ricks, Lilly chair and CEO. “At the…
Eli Lilly Stock Jumps on Earnings Beat Fueled by Weight-Loss Drugs
Eli Lilly hikes its full-year guidance after earnings handily beat analysts' forecasts.
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
Eli Lilly and Co raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5% in premarket tradi...
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly reported second-quarter earnings and revenue that easily beat estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment ...
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAA...
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-qua...
Here's How Much Traders See Eli Lilly Stock Moving After Earnings
Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker's stock could potentially approach last month's highs following the results.
JPMorgan names 3 stocks worth buying ahead of August earnings
US stock market is entering August against a turbulent backdrop, featuring continued Iran-driven volatility in oil prices and an ongoing earnings season. Plus, investors are still processing the recen...
Eli Lilly to offer early access to next-gen obesity drug to some patients
Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Eli Lilly tells Stat it will let more patients apply for retatrutide access
An Eli Lilly (LLY) spokesperson confirmed to Stat News that it will allow other patients to apply for early access to retatrutide, an unapproved obesity drug. The news comes six…
Eli Lilly Stock (LLY) Is Down Nearly 10% Heading into Earnings. Time to Buy?
The company’s Q2 results will be the first to include sales of its obesity pill.
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...